REstoration of Communication and LAnguage With Intracortical Microelectrodes (RECLAIM)
Early Feasibility Study of the Restoration of Communication and Language With Intracortical Microelectrodes (RECLAIM) System
The purpose of this study is to investigate the safety and feasibility of using distributed intracortical recordings from the language network to decode intended language output in individuals with severe communication impairment due to severe communication impairment resulting from amyotrophic lateral sclerosis (ALS), locked-in syndrome, and brain injury including from stroke.
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Undersøgelsestype
Undersøgelsestype
Tilmelding (Anslået)
Tilmelding
Fase
Fase
- Ikke anvendelig
Kontakter og lokationer
Studiekontakt
Studiekontakt
- Navn: Nitin Tandon, MD
- Telefonnummer: (713) 500-5456
- E-mail: Nitin.Tandon@uth.tmc.edu
Undersøgelse Kontakt Backup
- Navn: Eliana Klier, PhD
- Telefonnummer: (713) 500-5442
- E-mail: Eliana.Klier@uth.tmc.edu
Studiesteder
-
-
Texas
-
Houston, Texas, Forenede Stater, 77030
- The University of Texas Health Science Center at Houston
-
Ledende efterforsker:
- Nitin Tandon, MD
-
Kontakt:
- Nitin Tandon, MD
- Telefonnummer: (713) 500-5456
- E-mail: Nitin.Tandon@uth.tmc.edu
-
Kontakt:
- Eliana Klier, PhD
- Telefonnummer: (713) 500-5442
- E-mail: Eliana.Klier@uth.tmc.edu
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
-
Clinical diagnosis of ALS, locked-in syndrome, or stroke
- ALS - ALS patients who in the opinion of the treating neurologist have at least 3 years of survival
- Locked-in Syndrome as a result of brain-stem stroke or traumatic brain-stem injury - patients who in the opinion of the treating neurologist have at least 3 years of survival
- Stroke (either ischemic or hemorrhagic) - for patients with prior stroke, the original cause of the stroke (e.g., arteriovenous malformation, carotid stenosis, atrial fibrillation, heart disease, hypertension) must have been addressed and the patient must not have had a recurrent stroke at least within the prior 12 months
-
ALS diagnosis, stroke, or Locked-in syndrome (LIS) etiology onset occurred at least one year prior to enrollment
-
Minimal communication ability as assessed by a speech-language pathologist
- unable to produce more than 10 total unique intelligible words when reading the Rainbow Passage and Grandfather Passage, and
- unable to write or type more than 10 unique words from a dictated list of 20 words.
-
Limited upper limb strength based on the Medical Research Council Scale for Muscle Strength
- ≤3/5 strength throughout both arms for those with non-progressive conditions (stroke or traumatic brain-stem injury)
- ≤4/5 strength throughout both arms for those with ALS
i. For patients with 4/5 strength, they must have a documented decline in speech or upper extremity function in the preceding 12 months.
-
Has a means of communication sufficient to enable understanding of research protocol and provide consent (e.g. eye blinks or eye movements, use of assistive technology). Thus patients are severely impaired with regards to naturalistic communication, but able to make decisions regarding their own care
-
Ability to understand and comply with study session instructions
-
Must live within a 90-minute drive of study site and willing to travel to study site up to three days per week for duration of the study
-
Has a stable psychosocial support system with caregiver capable of providing care during post-operative periods and monitoring participant throughout the study
-
Stable ventilator status - ventilator requirements have not changed over prior 6 months and ventilator status does not impose additional substantial risks to subject participation, including travel to the investigation site
Exclusion Criteria:
- Psychiatric conditions including current diagnosis of major psychiatric illness, significant cognitive impairment (based on a neuropsychological assessment by a clinical psychologist), suicidal ideation with intent/plan. [Columbia-Suicide Severity Rating Scale (C-SSRS) Categories 4-5)] or suicidal behavior within 12 months, or substance abuse/narcotic/alcohol dependence within 12 months.
- Neurological disorders including current diagnosis of epilepsy, abnormal pre-surgical neuroimaging precluding safe implant placement (per neurosurgical team), prior ipsilateral craniotomy, or hydrocephalus with or without ventricular shunt.
- Implanted electronic devices including pacemakers, cardiac defibrillators, spinal cord stimulators, vagal nerve stimulators, deep brain stimulators, or cochlear implants.
- Cardiovascular disorders including acute myocardial infarction (MI) or cardiac arrest within 6 months, significant cardiovascular impairment contraindicating surgery.
- Hematological disorders requiring chronic anticoagulation and medical contraindication to discontinuing anticoagulant medications perioperatively.
- Dermatological conditions causing excessive skin sloughing, poor wound healing, existing scalp lesions, or skin breakdown.
- Infectious/immunological conditions including active infections, unexplained fever, HIV infection, ongoing chronic infections, medical conditions predisposing to high infection risk, chronic steroid or immunosuppressive therapy, or active cancer within 1 year requiring chemotherapy.
- Medical contraindications including conditions contraindicating chronically implanted devices (osteomyelitis, diabetes, hepatic failure, autoimmune disease/disorders with associated altered immune responses) or other chronic unstable medical conditions interfering with participation.
- Surgical contraindications including medical contraindications to general anesthesia, craniotomy, or surgery; significant pulmonary, metabolic, or renal impairments making surgical procedure unsafe.
- Other exclusions including pregnancy (confirmed by blood test), nursing, inadequate contraception, correction vision worse than 20/100, limited English proficiency, or concurrent participation in device/drug trials.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Andet
- Tildeling: N/A
- Interventionel model: Enkelt gruppeopgave
- Maskning: Ingen (Åben etiket)
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Eksperimentel: RECLAIM System
|
6 microelectrode grids will be implanted within the dominant hemisphere, placed across key speech and language cortical regions. The device will be kept implanted for up to 5 years and study sessions will be conducted 3-5 times per week |
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Safety as assessed by the number and type of adverse events that occur
Tidsramme: From time of implant to one year post-implant
|
From time of implant to one year post-implant
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Safety as assessed by the number of participants with device explanted
Tidsramme: From time of implant to one year post-implant
|
From time of implant to one year post-implant
|
|
|
Safety as assessed by the number of participants with Serious Adverse Events that result in death or permanently increased disability
Tidsramme: From time of implant to one year post-implant
|
From time of implant to one year post-implant
|
|
|
Effectiveness of the device as assessed by the Word error rate (WER)
Tidsramme: Every three months for the first two years post-implant
|
Every three months for the first two years post-implant
|
|
|
Effectiveness of device as assessed by the Phoneme error rate (PER)
Tidsramme: Every three months for the first two years post-implant
|
Every three months for the first two years post-implant
|
|
|
Effectiveness of the device as assessed by the Bilingual Evaluation Understudy (BLEU) Score
Tidsramme: Every three months for the first two years post-implant
|
BLEU (Bilingual Evaluation Understudy) quantifies, on a range of 0-1, the overlap between the decoded text and the reference text based on matching n-grams. Higher BLEU scores indicate that the decoded output more closely matches the reference at the level of local word sequences. |
Every three months for the first two years post-implant
|
|
Effectiveness of the device as assessed by the Bidirectional Encoder Representations from Transformers (BERT) Score
Tidsramme: Every three months for the first two years post-implant
|
BERT Score compares the semantic similarity (on a range of -1 to 1) between the decoded text sequence and the reference text using a pretrained language model (BERT). Higher scores indicated stronger semantic alignment. |
Every three months for the first two years post-implant
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Datoer for undersøgelser
Studer store datoer
Studiestart (Anslået)
Studiestart
Primær færdiggørelse (Anslået)
Primær færdiggørelse
Studieafslutning (Anslået)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Neurologiske manifestationer
- Cerebrovaskulære lidelser
- Hjernesygdomme
- Sygdomme i centralnervesystemet
- Sygdomme i nervesystemet
- Karsygdomme
- Hjerte-kar-sygdomme
- Psykiske lidelser
- Sår og skader
- Neuromuskulære sygdomme
- Metaboliske sygdomme
- Neuroadfærdsmæssige manifestationer
- Neurodegenerative sygdomme
- Neuroudviklingsforstyrrelser
- Kraniocerebralt traume
- Traumer, nervesystemet
- Rygmarvssygdomme
- TDP-43 Proteinopatier
- Proteostase mangler
- Motor neuron sygdom
- Lammelse
- Quadriplegi
- Patologiske tilstande, tegn og symptomer
- Ernæringsmæssige og metaboliske sygdomme
- Tegn og symptomer
- Locked-in syndrom
- Slag
- Hjerneskader
- Amyotrofisk lateral sklerose
- Kommunikationsforstyrrelser
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- HSC-MS-26-0020
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .